Literature DB >> 19001437

A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death.

Tabitha E Wood1, Shadi Dalili, Craig D Simpson, Rose Hurren, Xinliang Mao, Fernando Suarez Saiz, Marcela Gronda, Yanina Eberhard, Mark D Minden, Philip J Bilan, Amira Klip, Robert A Batey, Aaron D Schimmer.   

Abstract

Evasion of death receptor ligand-induced apoptosis is an important contributor to cancer development and progression. Therefore, molecules that restore sensitivity to death receptor stimuli would be important tools to better understand this biological pathway and potential leads for therapeutic adjuncts. Previously, the small-molecule N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide (fasentin) was identified as a chemical sensitizer to the death receptor stimuli FAS and tumor necrosis factor apoptosis-inducing ligand, but its mechanism of action was unknown. Here, we determined that fasentin alters expression of genes associated with nutrient and glucose deprivation. Consistent with this finding, culturing cells in low-glucose medium recapitulated the effects of fasentin and sensitized cells to FAS. Moreover, we showed that fasentin inhibited glucose uptake. Using virtual docking studies with a homology model of the glucose transport protein GLUT1, fasentin interacted with a unique site in the intracellular channel of this protein. Additional chemical studies with other GLUT inhibitors and analogues of fasentin supported a role for partial inhibition of glucose transport as a mechanism to sensitize cells to death receptor stimuli. Thus, fasentin is a novel inhibitor of glucose transport that blocks glucose uptake and highlights a new mechanism to sensitize cells to death ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001437     DOI: 10.1158/1535-7163.MCT-08-0569

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  61 in total

1.  Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality.

Authors:  Denise A Chan; Patrick D Sutphin; Phuong Nguyen; Sandra Turcotte; Edwin W Lai; Alice Banh; Gloria E Reynolds; Jen-Tsan Chi; Jason Wu; David E Solow-Cordero; Muriel Bonnet; Jack U Flanagan; Donna M Bouley; Edward E Graves; William A Denny; Michael P Hay; Amato J Giaccia
Journal:  Sci Transl Med       Date:  2011-08-03       Impact factor: 17.956

2.  Anticancer agents interacting with membrane glucose transporters.

Authors:  C Granchi; S Fortunato; F Minutolo
Journal:  Medchemcomm       Date:  2016-07-08       Impact factor: 3.597

3.  Structure guided design and synthesis of furyl thiazolidinedione derivatives as inhibitors of GLUT 1 and GLUT 4, and evaluation of their anti-leukemic potential.

Authors:  Kalpana Tilekar; Neha Upadhyay; Jessica D Hess; Lucasantiago Henze Macias; Piotr Mrowka; Renato J Aguilera; Franz-Josef Meyer-Almes; Cristina V Iancu; Jun-Yong Choe; C S Ramaa
Journal:  Eur J Med Chem       Date:  2020-07-02       Impact factor: 6.514

4.  18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Misu Lee; Jeong Yong Jeon; Micheal L Neugent; Jung-Whan Kim; Mijin Yun
Journal:  Clin Exp Metastasis       Date:  2017-04-20       Impact factor: 5.150

Review 5.  The Warburg effect: evolving interpretations of an established concept.

Authors:  Xiaozhuo Chen; Yanrong Qian; Shiyong Wu
Journal:  Free Radic Biol Med       Date:  2014-09-30       Impact factor: 7.376

Review 6.  Non-coding RNAs: emerging regulators of glucose metabolism in hepatocellular carcinoma.

Authors:  Yongting Lai; Hairong Huang; Mubalake Abudoureyimu; Xinrong Lin; Chuan Tian; Ting Wang; Xiaoyuan Chu; Rui Wang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

7.  Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays.

Authors:  Rachel Airley; Andrew Evans; Ali Mobasheri; Stephen M Hewitt
Journal:  Ann Anat       Date:  2010-03-24       Impact factor: 2.698

8.  Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents.

Authors:  Muriel Bonnet; Jack U Flanagan; Denise A Chan; Amato J Giaccia; Michael P Hay
Journal:  Bioorg Med Chem       Date:  2013-12-20       Impact factor: 3.641

Review 9.  Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer.

Authors:  Kalpana Tilekar; Neha Upadhyay; Cristina V Iancu; Vadim Pokrovsky; Jun-Yong Choe; C S Ramaa
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-10-21       Impact factor: 10.680

Review 10.  Glucose transporters in cancer metabolism.

Authors:  Kehinde Adekola; Steven T Rosen; Mala Shanmugam
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.